Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWIND.
Diabetes CareSep 22, 2026
Naveed Sattar, Hertzel C Gerstein, David D'Alessio et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial analyzed the cardiovascular effects of tirzepatide compared to an imputed placebo using data from the SURPASS-CVOT and REWIND trials. In participants with type 2 diabetes and established atherosclerotic cardiovascular disease, tirzepatide was associated with a significant reduction in major adverse cardiovascular events (MACE-3) with a hazard ratio of 0.72 (95% CI 0.55, 0.94).
Key findings
- Tirzepatide was associated with a lower MACE-3 (HR 0.72; 95% CI 0.55, 0.94).
- The treatment also reduced death from cardiovascular causes or heart failure events (HR 0.70; 95% CI 0.51, 0.96).
- All-cause mortality was significantly lower with tirzepatide (HR 0.61; 95% CI 0.45, 0.82).
Why it matters
The findings suggest that tirzepatide may provide significant cardiovascular benefits in patients with type 2 diabetes and established cardiovascular disease, which is crucial for managing this high-risk population.